ASX · PTX.AX
Prescient Therapeutics Limited
A$0.05-A$0.00 (-1.82%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 56.8% below the high.
Loading market information…
ASX · NSB.AX · AUD
Stock price, earnings
Quote as of Oct 27, 2026, 02:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
NeuroScientific Biopharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow NeuroScientific Biopharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.05-A$0.00 (-1.82%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 56.8% below the high.
A$0.02+A$0.00 (+6.25%)
AnteoTech Limited’s quoted price sits in the lower half of its reported 52-week range, 65.31% below the high.
A$0.09-A$0.00 (-1.12%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.0% below the high.
A$0.15A$0.00 (0.0%)
Next Science Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
A$0.10-A$0.01 (-4.76%)
Doctor Care Anywhere Group PLC’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
A$0.12+A$0.00 (+2.56%)
Proteomics International Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 86.05% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
A$0.12+A$0.01 (+9.52%)
Argenica Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
